아토피피부염의 치료 = Treatment for atopic dermatitis

다국어 초록 (Multilingual Abstract)

Atopic dermatitis (AD) is the most common chronic skin disease of young children and poses a significant globalhealth problem. More than half of children with AD develop asthma and allergies, typically in the first few years oftheir life. AD is a paradigmatically complex disease with a number of contributing factors, which include genetics,the environment, infection, and skin barrier dysfunction. The diverse clinical phenotypes of AD reflect the geneticand epigenetic background affecting the innate and adaptive immune system, as well as neuro-immunological andenvironmental factors including microbiologic signals. The gold standard for the management of AD is efficient,ideally proactive, anti-inflammatory treatment combined with strategies aimed at restoring the epidermal barrier.

This includes avoidance of trigger factors, skin barrier repair and maintenance, and the use of anti-inflammatoryagents. Basic skin care is also considered an important pillar in the management of AD, with functional emollientsbeginning to appear on the market. In addition, a number of new candidate molecules for the treatment of ADare currently under investigation in clinical trials. Last but not least, treatment compliance remains a key factor forthe successful management of AD. Due to its complex clinical phenotype, the future management of AD shouldbe more individualized, addressing personal clinical and genetic/biologic

참고문헌 (Reference)

1 Werfel T, "Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, ran-domized, dose-response study" 61 : 202-205, 2006

2 Lane JE, "Treatment of recalcitrant atopic dermatitis with omalizumab" 54 : 68-72, 2006

3 Kim KH, "Textbook of dermatology" Medbook 202-213, 2014

4 Nicol NH, "Successful strategies in atopic der-matitis management" (Suppl) : 3-18, 2008

5 Pajno GB, "Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study" 120 : 164-170, 2007

6 Sidbury R, "Random-ized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study" 159 : 245-247, 2008

7 Kalliomaki M, "Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial" 357 : 1076-1079, 2001

8 Kalliomaki M, "Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial" 361 : 1869-1871, 2003

9 Wolverton SE, "Optimizing clinical use of azathioprine with newer pharmacogenetic data" 145 : 707-710, 2009

10 Krakowski AC, "Management of atopic dermatitis in the pediatric population" 122 : 812-824, 2008

11 Papp KA, "Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study" 52 : 240-246, 2005

12 Devillers AC, "Efficacy and safety of ‘wet-wrapʼ dres-sings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature" 154 : 579-585, 2006

13 Hanifin JM, "Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis" 53 (53): S186-S194, 2005

14 Rosenfeldt V, "Effect of probiotic Lactobacillus strains in children with atopic dermatitis" 111 : 389-395, 2003

15 Takiguchi R, "Efalizumab for severe atopic dermatitis: a pilot study in adults" 56 : 222-227, 2007

16 Akdis CA, "Diagnosis and treatment of atopic der-matitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report" 118 : 152-169, 2006

17 Boguniewicz M, "A multidiscipli-nary approach to evaluation and treatment of atopic dermatitis" 27 : 115-127, 2008